LearnSkin

Optimizing Clinical Decision-Making and Competence in JAK Inhibitor Therapy for Vitiligo

Managing Non-Segmental Vitiligo in Sensitive Facial Areas

0.25 CME Credits
509 Enrolled
Supported by an independent educational grant from Incyte

Course Overview

Preview what you'll learn in this program

0hr 15min
Duration
0.25
Credits
Nov 2025
Released
Jul 2026
Expires
89% avg
Completion

What You'll Learn

This microlearning activity explores treatment considerations for non-segmental vitiligo localized to sensitive facial regions, highlighting strategies to balance effectiveness and safety.

Target Audience

This activity has been designed to meet the educational needs of clinicians and non-clinicians involved in the care of patients with vitiligo.

Disclosure of Conflicts of Interest

Your CE Source ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, Your CE Source identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Your CE Source to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Your CE Source is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of FacultyReported Financial Relationship

Seemal R Desai, MD FAAD

Speaker Disclosures:

  • Consultant: Galderma Laboratories, LP, Almirall, Ferndale Laboratories, Inc., Gore Range Capital, Bristol-Myers Squibb, AbbVie Verrica Pharmaceuticals, Inc., UCB, Ortho
  • Speaker: Pfizer Inc.
  • Board Member or Executive: Foundation for Research & Education of Dermatology Dermavant Sciences, Womens Derm Society
  • Contracted Research: AbbVie, Incyte Corporation, Dermavant Sciences, Inc., AOBiome, LLC
  • Which of the following is the most appropriate initial treatment option?Gore Range Capital

Other Financial Relationship: National Psoriasis Foundation

Name of Editor / Scientific ReviewerReported Financial Relationship

James Song, MD

Advisory Board: Janssen, Castle Bioscience, AbbVie, Novartis, UCB, Eli Lily, Acrutis, Incyte, SUN, Amgen

Speakers Bureau: AbbVie, Novartis, UCB, Eli Lily, Incyte, SUN, Amgen

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Content ManagerReported Financial Relationship

James Song, MD

Advisory Board: Janssen, Castle Bioscience, AbbVie, Novartis, UCB, Eli Lily, Acrutis, Incyte, SUN, Amgen

Speakers Bureau: AbbVie, Novartis, UCB, Eli Lily, Incyte, SUN, Amgen

Planners at Your CE Source

No relationships with a commercial interest to disclose

All other faculty, planner and/or content managers have nothing to disclose nor do they have any vested interests or affiliations. All conflicts of interest have been resolved.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Your CE Source and LearnHealth. Your CE Source is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Your CE Source designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

This CE activity provides 0.25 contact hour of continuing nursing education. Your CE Source is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 16031.

Method of Participation

Participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each quiz question, and 4) complete the evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. Statements of credit will be available once the evaluation form is completed.

Disclaimer

The content, views, and opinions presented in this educational activity are those of the faculty/authors and do not necessarily reflect those of Incyte, Your CE Source, and/or LearnHealth. The faculty/authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Learners are required to adhere to the privacy and confidentiality policy as it relates to the CE activities provided on the Internet. Please see the policy at https://www.yourcesource.org

Contact Information

Your CE Source Logo
Your CE Source Logo

This activity is jointly provided by Your CE Source and LearnHealth.

Questions about CE accreditation or CE certificates related to this course, please contact us via email at [email protected]. For all other questions, please contact [email protected].

Faculty

Editors

Accreditation Information

This microlearning activity explores treatment considerations for non-segmental vitiligo localized to sensitive facial regions, highlighting strategies to balance effectiveness and safety.

Target Audience

This activity has been designed to meet the educational needs of clinicians and non-clinicians involved in the care of patients with vitiligo.

Disclosure of Conflicts of Interest

Your CE Source ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, Your CE Source identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by Your CE Source to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Your CE Source is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of FacultyReported Financial Relationship

Seemal R Desai, MD FAAD

Speaker Disclosures:

  • Consultant: Galderma Laboratories, LP, Almirall, Ferndale Laboratories, Inc., Gore Range Capital, Bristol-Myers Squibb, AbbVie Verrica Pharmaceuticals, Inc., UCB, Ortho
  • Speaker: Pfizer Inc.
  • Board Member or Executive: Foundation for Research & Education of Dermatology Dermavant Sciences, Womens Derm Society
  • Contracted Research: AbbVie, Incyte Corporation, Dermavant Sciences, Inc., AOBiome, LLC
  • Which of the following is the most appropriate initial treatment option?Gore Range Capital

Other Financial Relationship: National Psoriasis Foundation

Name of Editor / Scientific ReviewerReported Financial Relationship

James Song, MD

Advisory Board: Janssen, Castle Bioscience, AbbVie, Novartis, UCB, Eli Lily, Acrutis, Incyte, SUN, Amgen

Speakers Bureau: AbbVie, Novartis, UCB, Eli Lily, Incyte, SUN, Amgen

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Name of Content ManagerReported Financial Relationship

James Song, MD

Advisory Board: Janssen, Castle Bioscience, AbbVie, Novartis, UCB, Eli Lily, Acrutis, Incyte, SUN, Amgen

Speakers Bureau: AbbVie, Novartis, UCB, Eli Lily, Incyte, SUN, Amgen

Planners at Your CE Source

No relationships with a commercial interest to disclose

All other faculty, planner and/or content managers have nothing to disclose nor do they have any vested interests or affiliations. All conflicts of interest have been resolved.

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Your CE Source and LearnHealth. Your CE Source is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Your CE Source designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

This CE activity provides 0.25 contact hour of continuing nursing education. Your CE Source is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 16031.

Method of Participation

Participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each quiz question, and 4) complete the evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. Statements of credit will be available once the evaluation form is completed.

Disclaimer

The content, views, and opinions presented in this educational activity are those of the faculty/authors and do not necessarily reflect those of Incyte, Your CE Source, and/or LearnHealth. The faculty/authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Learners are required to adhere to the privacy and confidentiality policy as it relates to the CE activities provided on the Internet. Please see the policy at https://www.yourcesource.org

✨ Ready to Begin Your Journey? ✨

Enroll now to start the course and unlock all learning materials

Login

Quiz

CME Certificate

0.25 CME Credits

Complete Requirements to Unlock

Finish the post-quiz and course evaluation to receive your certificate

  • Pass post-quiz (0% or higher)

Course Discussion

Join the conversation with fellow learners

Continue Your Learning Journey

Next course in Optimizing Clinical Decision-Making and Competence in JAK Inhibitor Therapy for Vitiligo

Treating Facial Vitiligo in a 32-Year-Old Female
Next in Series
Course in series

Treating Facial Vitiligo in a 32-Year-Old Female

Gain clinical insights into managing facial vitiligo in a 32-year-old female through diagnosis, treatment strategies, and personalized care approaches.

CME
Start Next Course
LearnSkin Logo
All material on this website is protected by copyright. Copyright © LearnHealth Inc. 2026.
This website also contains material copyrighted by 3rd parties.
ABOUT
LEGAL
SUBSCRIBE
To Get Posts Directly In Your Inbox!